Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Are these getting very much ahead of kanabo though and positioning themselves to dominate the market? Maybe another tobacco firm will come in for kanabo to rival. I think kanabo’s vape pod is better than their inhaler
SYQE MEDICAL for $650m and their main product is a similar to the Kanabo inhaler
https://mjbizdaily.com/philip-morris-buying-israeli-cannabis-firm-for-up-to-650m-report-says/
Whilst the price is still flagging it does not reflect on the sentiment thats growing
https://www.proactiveinvestors.co.uk/companies/news/1021029/gps-prescribing-cannabis-could-ease-nhs-wait-times-report-1021029.html
No figure; but they mentioned its substantial revenues generating contract.
Placing is done at 2.25 p , cash is in.
re-rate is starting
This big publicised crackdown looks more like the governments attempt to clear the way for the legal route as they are fully aware potential revenues that lie ahead. The sector could be ready to make a big move forward despite what the stock prices are saying and these raids are a positive step towards that..
Https://www.thisismoney.co.uk/money/article-12259611/SMALL-CAP-IDEA-Cannabis-businesses.html
I’m sure CE approval is only in Q3. However; I fully agree there are some solid foundations here. I think if they reduce operating costs (merger of GP service now behind us) and increase revenues (treat it for this year too) then I believe this will fly on the next set of financial results. These markets will only become more popular in my opinion. Just need that breakthrough deal to send this flying.
Can someone summarise the RNS is In layman terms please?
Also, first time I’ve seen 2 Mm’s on the bid, looks poised to move up imo.
Perhaps news on the CE marked measured dose unit due, I think this will have a significant impact, especially if KNB are already in discussions with European partner.
I think there are a number of interesting moving parts to this Company and feel they have put in some solid foundations, perhaps some of Mattioli’s Investors will start to follow his lead?
Anyone found a reason why a 12% rise yesterday and 3.6% today?
Looks as if this could move up swiftly on a few more buys.
Bit odd to see sells down here but they’re just small trades, maybe an algobot set to keep this in a range whilst someone accumulates?…….
https://*********************/newsfeed/article/kanabo-group-plc-full-year-results-2022-1823055
RNS tomorrow giving full year revenue for 22 GBP £603,000 should stop the drop so I would say this is as low as she will go. But I have been wrong before.
I’ve been thinking more about Ian Mattioli recently investing £500K into Kanabo & taking the position of Non-executive Chairman.
People should research him and come to their own conclusions about the rationale to invest a relatively large sum in a small Company. He’s a shrewd businessman but cautious too.
The potential market for Medical Cannabis is simply enormous.
KNB has a current MCap of £10M, £2.5M in cash and owns The GP Service, which it paid around £15M for.
The Company has recently launched ‘Treat it’ , an online service aimed at specialist pain treatment.
Telemedicine in itself is growing very quickly, ignoring the fact that KNB, via The GP service, has access to all NHS records.
Furthermore, we have US Patent -pending formula for sleep disorders.
The Company is building some very solid foundations both in medicinal cannabis & digital health services.
That’s interesting, good link spmx.
30th June 22 last AGM
The Medical Cannabis prescription figures released in Guernsey look very promising
https://www.itv.com/news/channel/2023-06-08/guernsey-gives-out-12000-cannabis-prescriptions-in-10-months
Its a year today since the last AGM and with another one due shortly then it would be good to see it supported with some encouraging news
Yes its great having him onboard and it gives confidence to the market especially with his investment however from the inflated IPO price we have seen it heavily fall with those that bought in at the top end needing more than a miracle compared to his investment price.
New small cap companies prefer the price to fall following an IPO so there's less risk if they need new cash calls because many initial retail investors sitting on big holdings at the higher price are not affiliated with the company making it difficult to raise cash from them hence bringing Ian Mattoli onboard at a far lower risk to him than the initial retail investors and they achieve another cash injection. He was also given a seat on the board but I just hope he stays around with his investment until this gets back closer to the initial IPO price.
This appointment also reinforces the professionalism and commitment to building a serious quality Company.
Ian Mattioli wouldn’t have taken the Position if he wasn’t impressed with the Company, and optimistic about its future.
I suspect the next key announcement will be the European CE approval for the Groups Unique meter dose cannabis inhaler. Approval expected in the 3rd quarter, so anytime from July 2023 onwards.
Interesting that he has come aboard here.
I’ve done some research on his own Company and he is very shrewd.
“We remind readers that acquisitive growth is a core part of MW’s strategy. It has a long track record of success with 34 acquisitions (excluding White) since its admission to AIM in 2005.”
I expect to see KNB grow rapidly through acquisitions now the foundations & technology platform are in place. Very interesting appointment indeed.
Good opportunity to buy at a 35% discount to the recent placing imo.
Still waiting for the proposed date of the AGM and all resolutions to be passed including those shares allocated to the officers and directors.
Tomorrow will bring another admission of shares associated with the purchase of the GP Service and with the AGM announcement due hopefully with both behind us we can see some upward movement from the current level. Over the last month we have seen the total issued shares increased by approx 20% so hopefully from here we can see some meat on the bones from the company to justify their current dilution strategy.
Obviously as the share price has crashed since the debt facility loan was made and where the price is now then it's not beneficial to issue the shares to MIEF as the exercise price was 12.65p per share..With them obtaining an extension to Dec 24 then they must be confident in reaching this price with the option to issue them sooner.than the extension deadline . Lets hope their confidence translates into the share price rebound and this exercise price is surpassed in the short to medium term with long term holders believing they can also profit from their investment too.
As announced on 21 February 2022, as part-consideration for the acquisition of The GP Service Limited, Kanabo was due to issue 12,574,931 new Ordinary Shares to MEIF WM Debt LP ("MEIF") on or around 22 August 2023, at an issue price of 12.65p per share.
-- Following the successful completion of the GBP2.74 million fundraise by the Company earlier this month, and with the consent of MEIF, the Company believes that it was beneficial for all stakeholders that the issuance date of these consideration shares should be extended to 31 December 2024.
-- All other terms of the original February 2022 agreement, aside from this extension date, remain the same, including t he number of shares to be issued, 12,574,931 and the issue price of 12.65p.
Ive just paid 2.9 to buy so will show red
Lots of buys being printed red. I reckon once the loose shares clear under 2.9 then we firm up nicely above 3p while we await news.